Table 3.
Efficacy outcomes
| Treatment sequence | ABI-DOCE (n = 178) |
ABI-ENZA (n = 99) |
ABI-RAD (n = 27) |
DOCE-ABI (n = 191) |
DOCE-CABA (n = 74) |
DOCE-ENZA (n = 116) |
ENZA-DOCE (n = 42) |
|---|---|---|---|---|---|---|---|
| Time to progression (mo)a, median (95% CI) | 5.8 (5.3–7.2) | 8.7 (6.2–10.8) | 6.2 (4.3–9.9) | 7.4 (6.7–8.0) | 7.1 (6.0–8.3) | 8.1 (7.1–9.0) | 7.6 (4.8–9.3) |
| Progression-free survival 2 (mo)b, median (95% CI) | 15.9 (14.4–17.6) | 20.1 (16.3–22.5) | 16.5 (12.6–23.6) | 15.7 (14.3–16.8) | 11.0 (9.9–14.4) | 16.2 (13.1–17.1) | 16.9 (13.9–18.0) |
| Overall survival (mo)c, median (95% CI) | 27.0 (22.1–28.9) | 30.8 (26.7–NE) | 29.0 (17.1–NE) | NE (31.4–NE) | 22.3 (16.2–29.8) | 31.5 (25.9–35.5) | 28.1 (20.0–NE) |
ABI = abiraterone acetate plus prednisone/prednisolone; CABA = cabazitaxel; CI = confidence interval; DOCE = docetaxel; ENZA = enzalutamide; mCRPC = metastatic castration-resistant prostate cancer; NE = not estimable; RAD = radium-223.
Measured from the start date of the first mCRPC treatment to the start date of the second treatment. Time to progression was censored after the start of the second treatment. Patients with no progression at the end of registry are censored.
Measured from the start of first treatment to progression/death after the start of second treatment. Patients with no progression at the end of registry are censored.
Measured from the start date of mCRPC treatment to the date of death (irrespective of cause); survival time of living patients was censored at the last date a patient was known to be alive (for those withdrawn from the study) or the end-of-registry date.